<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=US-ASCII">
<title>Insert title here</title>
<link rel="stylesheet" type="text/css" href="css/bootstrap.min.css">
<link rel="stylesheet" type="text/css" href="css/bootstrap-theme.min.css">
<link rel="stylesheet" type="text/css" href="css/main.css">
<link rel="stylesheet" href="js/jstree/themes/default/style.min.css" />
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/jquery-ui-1.10.4.min.js"></script>
<script type="text/javascript" src="js/bootstrap.min.js"></script>
<script type="text/javascript" src="js/spin.min.js"></script>
<script type="text/javascript" src="js/main.js"></script>
<script src="http://yui.yahooapis.com/3.16.0/build/yui/yui-min.js"></script>
<script type="text/javascript" src="js/jstree/jstree.min.js"></script>
</head>
<body>
	<div class="container">
		<h2 class="page-header">Treatment options <img src="images/genomics.png" width="50px" height="50px" /></h2>
		<div class="row">
			<div class="col-md-6">
			<p class="lead">Based upon patient history, molecular profile and available clinical trials, here are the recommended treatment options
				
			</p>
			</div>
			<div class="col-md-12 well">
				<ol>
					<li><b>Lapatinib: </b>Lapatinib is a dual anti-HER1 and HER2 agent, HER1 testing cannot be used for prediction (NCCN guideline), 
					and there is data on lapatinib effect when HER2 is low/neg. Lapatinib is appropriate for her because it has been shown to be effective 
					in low her2 patients who have her2 pathway activated. It is not off-compedium use so payers will reimburse.
					Lapatinib is also relevant from a patient history perspective as we know that this patient has not been exposed to this drug and still have progressive disease.
					</li>
				</ol>
			
			</div>
		</div>
	</div>
</body>
</html>